What is Redhill Biopharma Ltd.'s earnings per share (EPS)?

Redhill Biopharma Ltd. (RDHL) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Redhill Biopharma Ltd. (RDHL) Financials

RDHL

FY2025 annual

Revenue $286K -96.4% YoY

Net Income -$429K +94.8% YoY

EPS (Diluted) $0.00 YoY not available

Free Cash Flow -$9.7M -3.0% YoY

Market Cap $3.9M as of Sep 12, 2026

Price / Sales 13.7x on $286K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Apr 27, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Apr 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RDHL SEC filings page.

Redhill Biopharma Ltd. (RDHL) reported $286K in revenue for fiscal year 2025, down 96.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RDHL FY2025 2026-09-05

Operating cash needs now dwarf reported revenue, leaving financing inflows to bridge a structurally cash-consuming business.

The FY2023 net profit of $23.9M coincided with operating cash flow of -$35.8M, revealing an accounting gain that did not become cash. By FY2025, revenue was just $286K while operating cash flow remained -$9.7M, showing cash use persisted even as the operating base contracted.

In FY2025, free cash flow nearly matched operating cash flow at roughly -$9.7M, while capital expenditures were immaterial; cash consumption is overwhelmingly operational rather than reinvestment-driven. Financing supplied $7.3M, partially offsetting that use rather than funding expansion.

A 0.3x current ratio means current resources were well below short-term obligations; reported liquidity equaled 4.9 months of the latest annual operating outflow, highlighting dependence on continued financing alongside weak near-term balance-sheet coverage.

Financial Health Signals

Financial health score not available

Redhill Biopharma Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/8

Redhill Biopharma Ltd. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Redhill Biopharma Ltd. reported a net loss of $429K while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q2 2025.

Cash & Balance Sheet

Cash & Debt

$2.9M

YoY-60.6%

QoQ-37.9%

Redhill Biopharma Ltd. held $2.9M in cash as of Q2 2025; long-term debt is not reported for that period.

Free Cash Flow

Not reported for Q2 2025.

Dividends Per Share

Not reported for Q2 2025.

Shares Outstanding

Not reported for Q2 2025.

Margins & Returns

None of these metrics is reported for Q2 2025.

Capital Allocation

None of these metrics is reported for Q2 2025.

RDHL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RDHL quarterly income statement

Metric	FY2520-F	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	$286K-96.4%	$8.0M+23.2%	$6.5M-89.4%	$61.8M-27.9%	$85.8M+33.2%	$64.4M+923.0%	$6.3M-24.7%	$8.4M+108.6%	$4.0M+3867.3%	$101K+3266.7%	$3K
Interest Expense	$19K-99.1%	$2.1M-78.6%	$9.6M-77.3%	$42.4M+154.4%	$16.7M+30.6%	$12.8M+2813.0%	$438K+162.3%	$167K+116.9%	$77K-79.5%	$375K+76.9%	$212K
Net Income	-$429K+94.8%	-$8.3M-134.6%	$23.9M+133.4%	-$71.7M+26.7%	-$97.7M-28.3%	-$76.2M-80.1%	-$42.3M-9.0%	-$38.8M+14.8%	-$45.5M-55.1%	-$29.4M-39.3%	-$21.1M
EPS (Basic)	$0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	231M+30.9%	177M+37.1%	129M+15.3%	112M

Metric	Q2'256-K/A	Q4'246-K/A	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q	Q4'2110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$18.3M-14.7%	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$4.2M-0.8%	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	-$11.7M+59.8%	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Income Tax, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

RDHL Balance Sheet

RDHL quarterly balance sheet

Metric	FY2520-F	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$25.3M+40.5%	$18.0M-21.7%	$23.0M-85.5%	$158.9M-12.3%	$181.2M+0.5%	$180.2M+143.2%	$74.1M+18.7%	$62.4M+8.8%	$57.3M-22.7%	$74.2M	N/A
Current Assets	$6.5M-45.2%	$11.9M-26.2%	$16.1M-81.2%	$85.9M-3.6%	$89.2M+26.5%	$70.5M+32.5%	$53.2M-6.3%	$56.8M+9.9%	$51.7M-23.8%	$67.8M	N/A
Cash & Equivalents	$4.0M-14.0%	$4.6M-17.1%	$5.6M-72.1%	$20.0M-32.3%	$29.5M+0.6%	$29.3M+0.9%	$29.0M+0.1%	$29.0M+76.3%	$16.5M-69.4%	$53.8M+150.0%	$21.5M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	$3.7M-16.8%	$4.4M-60.1%	$11.0M-25.7%	$14.8M+126.9%	$6.5M+246.8%	$1.9M+144.7%	$769K+17.8%	$653K	N/A	N/A
Accounts Receivable	N/A	$2.5M-2.0%	$2.6M-92.5%	$34.5M+9.0%	$31.7M+10.5%	$28.7M+2256.5%	$1.2M+26.9%	$958K-37.3%	$1.5M+1443.4%	$99K	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.1M-7.3%	$22.7M+8.3%	$21.0M-89.9%	$207.3M+20.3%	$172.3M+3.6%	$166.4M+1080.2%	$14.1M+25.6%	$11.2M-8.6%	$12.3M+6.7%	$11.5M	N/A
Current Liabilities	$19.2M-13.5%	$22.2M+11.2%	$20.0M-89.9%	$197.5M+142.4%	$81.5M+11.2%	$73.2M+589.9%	$10.6M+2.3%	$10.4M-12.2%	$11.8M+120.9%	$5.4M	N/A
Non-Current Liabilities	$1.9M+269.0%	$503K-49.4%	$995K-89.9%	$9.8M-89.2%	$90.8M-2.5%	$93.1M+2575.7%	$3.5M+312.4%	$844K+88.4%	$448K-92.7%	$6.2M	N/A
Long-Term Debt	$900K+29900.0%	$3K-99.3%	$455K-92.9%	$6.4M+150.3%	$2.6M-32.4%	$3.8M+27.7%	$3.0M+286.6%	$771K	N/A	N/A	N/A
Total Equity	$4.3M+191.1%	-$4.7M-326.3%	$2.1M+104.3%	-$48.4M-645.4%	$8.9M-36.0%	$13.9M-76.9%	$60.0M+17.2%	$51.2M+13.6%	$45.1M-28.1%	$62.7M+4.4%	$60.1M
Retained Earnings	-$413.8M+0.3%	-$414.8M-1.7%	-$407.7M+6.0%	-$433.9M-17.9%	-$367.9M-31.2%	-$280.3M-34.5%	-$208.4M-23.2%	-$169.1M-27.2%	-$132.9M-48.3%	-$89.6M	N/A

Metric	Q2'256-K/A	Q4'246-K/A	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q	Q4'2110-K
Total Assets	$18.4M-16.6%	$18.0M-21.7%	$22.0M-37.1%	$23.0M-85.5%	$35.0M-79.1%	$158.9M-12.3%	$168.0M-17.5%	$181.2M+0.5%
Current Assets	$12.6M-20.0%	$11.9M-26.2%	$15.7M-41.9%	$16.1M-81.2%	$27.0M-70.4%	$85.9M-3.6%	$91.3M-7.3%	$89.2M+26.5%
Cash & Equivalents	$2.9M-60.6%	$4.6M-17.1%	$7.3M+4.0%	$5.6M-72.1%	$7.0M-74.1%	$20.0M-32.3%	$27.0M-47.9%	$29.5M+0.6%
Inventory	$3.2M-16.7%	$3.7M-16.8%	$3.8M-23.0%	$4.4M-60.1%	$4.9M-57.9%	$11.0M-25.7%	$11.7M+33.7%	$14.8M+126.9%
Accounts Receivable	$5.3M+449.3%	$2.5M-2.0%	$974K-66.4%	$2.6M-92.5%	$2.9M-91.4%	$34.5M+9.0%	$33.8M+12.2%	$31.7M+10.5%
Total Liabilities	$22.8M+3.8%	$22.7M+8.3%	$22.0M-30.4%	$21.0M-89.9%	$31.6M-82.5%	$207.3M+20.3%	$179.9M+3.3%	$172.3M+3.6%
Current Liabilities	$22.3M+5.0%	$22.2M+11.2%	$21.2M-24.7%	$20.0M-89.9%	$28.2M-83.1%	$197.5M+142.4%	$166.4M+110.2%	$81.5M+11.2%
Non-Current Liabilities	$500K-31.5%	$503K-49.4%	$730K-78.4%	$995K-89.9%	$3.4M-75.0%	$9.8M-89.2%	$13.5M-85.8%	$90.8M-2.5%
Long-Term Debt	N/A	$3K-99.3%	$190K-80.9%	$455K-92.9%	$994K-85.1%	$6.4M+150.3%	$6.7M+124.1%	$2.6M-32.4%
Total Equity	-$4.4M-7332.8%	-$4.7M-326.3%	$61K-98.2%	$2.1M+104.3%	$3.5M+129.1%	-$48.4M-645.4%	-$11.9M-140.4%	$8.9M-36.0%
Retained Earnings	-$418.1M-2.0%	-$414.8M-1.7%	-$410.1M-7.3%	-$407.7M+6.0%	-$382.0M+3.8%	-$433.9M-17.9%	-$397.2M-21.8%	-$367.9M-31.2%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.

RDHL Cash Flow Statement

RDHL quarterly cash flow statement

Metric	FY2520-F	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$9.7M-3.0%	-$9.4M+73.8%	-$35.8M-22.7%	-$29.2M+55.1%	-$65.0M-33.9%	-$48.6M-19.2%	-$40.7M-18.2%	-$34.5M+23.0%	-$44.8M-58.4%	-$28.3M-58.5%	-$17.8M
Capital Expenditures	$5K-44.4%	$9K-18.2%	$11K-94.4%	$198K+72.2%	$115K-71.7%	$406K+141.7%	$168K+630.4%	$23K-84.2%	$146K+71.8%	$85K+507.1%	$14K
Free Cash Flow	-$9.7M-3.0%	-$9.4M+73.8%	-$35.8M-21.9%	-$29.4M+54.9%	-$65.2M-33.0%	-$49.0M-19.7%	-$40.9M-18.7%	-$34.5M+23.2%	-$44.9M-58.5%	-$28.3M-58.9%	-$17.8M
Investing Cash Flow	$1.7M+18888.9%	-$9K-325.0%	$4K-100.0%	$8.3M+202.0%	-$8.1M+77.2%	-$35.6M-790.3%	$5.2M-3.5%	$5.4M+128.8%	-$18.6M-175.9%	$24.5M+215.5%	-$21.2M
Financing Cash Flow	$7.3M-13.1%	$8.4M-60.7%	$21.4M+87.2%	$11.5M-84.4%	$73.5M-12.9%	$84.4M+137.6%	$35.5M-15.0%	$41.8M+62.8%	$25.7M-28.8%	$36.0M-34.3%	$54.8M

Metric	Q2'256-K/A	Q4'246-K/A	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q	Q4'2110-K
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$16.6M+12.3%	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$163K+5333.3%	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$16.7M+11.4%	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$163K+95.3%	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$14.9M+943.2%	N/A

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.

RDHL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RDHL quarterly financial ratios

Metric	FY2520-F	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Net Margin	-150.0%	-102.8%	366.3%	-116.0%	-114.0%	-118.4%	-672.5%	-464.4%	-1136.6%	-29079.2%	-703000.0%
Return on Equity	-10.1%	N/A	1155.9%	N/A	-1101.3%-551.9pp	-549.4%-478.9pp	-70.5%+5.3pp	-75.8%+25.2pp	-101.1%-54.2pp	-46.8%-11.7pp	-35.1%
Return on Assets	-1.7%+44.1pp	-45.8%-149.6pp	103.8%+148.9pp	-45.1%+8.8pp	-53.9%-11.7pp	-42.3%+14.8pp	-57.1%+5.1pp	-62.2%+17.2pp	-79.4%-39.8pp	-39.6%	N/A
Current Ratio	0.34-0.2x	0.54-0.3x	0.81+0.4x	0.43-0.7x	1.09+0.1x	0.96-4.0x	5.01-0.5x	5.47+1.1x	4.37-8.3x	12.66	N/A
Debt-to-Equity	0.21	N/A	0.22	N/A	0.290.0x	0.27+0.2x	0.050.0x	0.02-0.3x	0.27+0.1x	0.18	N/A
Asset Turnover	0.01-0.4x	0.45+0.2x	0.28-0.1x	0.39-0.1x	0.47+0.1x	0.36+0.3x	0.080.0x	0.13+0.1x	0.07+0.1x	0.00	N/A
FCF Margin	-3376.2%	-116.6%	-548.7%	-47.5%+28.4pp	-76.0%+0.1pp	-76.1%	-650.4%	-412.5%	-1120.9%	-28062.4%	-594666.7%

Metric	Q2'256-K/A	Q4'246-K/A	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q	Q4'2110-K
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-63.8%	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	-7.0%+7.3pp	N/A
Current Ratio	0.56-0.2x	0.54-0.3x	0.74-0.2x	0.81+0.4x	0.96+0.4x	0.43-0.7x	0.55-0.7x	1.09+0.1x
Debt-to-Equity	N/A	N/A	3.11+2.8x	0.22	0.29	N/A	N/A	0.290.0x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.110.0x	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-91.3%-3.4pp	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Return on Equity.

Note: The current ratio is below 1.0 (0.34), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Redhill Biopharma Ltd. RDHL	FY2025	$286K	-$429K	N/A	$3.9M	—
Shuttle Pharmaceuticals Holdings, Inc. SHPH	FY2025	N/A	-$11.7M	N/A	$2.1M	—
Inmed Pharmaceuticals Inc INM	FY2026	N/A	-$12.6M	N/A	$7.0M	—
PRF Technologies Ltd. PRFX	FY2025	$17K	-$5.0M	N/A	$3.2M	—
Sunshine Biopharma Inc SBFM	FY2025	$36.3M	-$6.0M	-16.5%	$4.2M	59/100
Cbdmd Inc YCBD	FY2025	$19.2M	-$2.0M	-10.6%	$5.4M	38/100

Where Redhill Biopharma Ltd. Ranks

Frequently Asked Questions

What is Redhill Biopharma Ltd.'s annual revenue?

Redhill Biopharma Ltd. (RDHL) reported $286K in total revenue for fiscal year 2025. This represents a -96.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Redhill Biopharma Ltd.'s revenue growing?

Redhill Biopharma Ltd. (RDHL) revenue declined by 96.4% year-over-year, from $8.0M to $286K in fiscal year 2025.

Is Redhill Biopharma Ltd. profitable?

No, Redhill Biopharma Ltd. (RDHL) reported a net income of -$429K in fiscal year 2025.

How much debt does Redhill Biopharma Ltd. have?

As of fiscal year 2025, Redhill Biopharma Ltd. (RDHL) had $4.0M in cash and equivalents against $900K in long-term debt.

What is Redhill Biopharma Ltd.'s return on equity (ROE)?

Redhill Biopharma Ltd. (RDHL) has a return on equity of -10.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Redhill Biopharma Ltd.'s free cash flow?

Redhill Biopharma Ltd. (RDHL) recorded an outflow of $9.7M in free cash flow during fiscal year 2025. This represents a -3.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Redhill Biopharma Ltd.'s operating cash flow?

Redhill Biopharma Ltd. (RDHL) recorded an outflow of $9.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Redhill Biopharma Ltd.'s total assets?

Redhill Biopharma Ltd. (RDHL) had $25.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Redhill Biopharma Ltd.'s capital expenditures?

Redhill Biopharma Ltd. (RDHL) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Redhill Biopharma Ltd. have outstanding?

Redhill Biopharma Ltd. (RDHL) had 50.92B shares outstanding as of fiscal year 2025.

What is Redhill Biopharma Ltd.'s current ratio?

Redhill Biopharma Ltd. (RDHL) had a current ratio of 0.34 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Redhill Biopharma Ltd.'s debt-to-equity ratio?

Redhill Biopharma Ltd. (RDHL) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Redhill Biopharma Ltd.'s return on assets (ROA)?

Redhill Biopharma Ltd. (RDHL) had a return on assets of -1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Redhill Biopharma Ltd.'s P/E ratio?

Redhill Biopharma Ltd. (RDHL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.9M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Redhill Biopharma Ltd.'s price-to-sales ratio?

Redhill Biopharma Ltd. (RDHL) trades at 13.7x sales, its market capitalization divided by revenue of $286K revenue, FY2025. The market capitalization is $3.9M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Redhill Biopharma Ltd.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Redhill Biopharma Ltd. (RDHL) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Redhill Biopharma Ltd.'s Piotroski F-Score?

Redhill Biopharma Ltd. (RDHL) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Redhill Biopharma Ltd.'s earnings high quality?

Redhill Biopharma Ltd. (RDHL) reported a net loss of $429K while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.